trial

European Long-acting Antipsychotics in Schizophrenia Trial

NCTId NCT02146547
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 536 (actual)
Sponsored by UMC Utrecht
Primary completion 2020-08-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
536 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2015-02
Primary completion
2020-08-26
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AripiprazolePaliperidone

Sponsors

UMC UtrechtLead Sponsor

Investigators

3
Rene S Kahn, professorPrincipal Investigator
Wolfgang Fleischhacker, professorPrincipal Investigator
Michael Davidson, professorPrincipal Investigator

Sites

49 total
Innsbruck, AustriaVienna, AustriaAntwerp, BelgiumAntwerp, BelgiumSofia, BulgariaHradec Králové, CzechiaBrno, CzechiaPrague, CzechiaGlostrup Municipality, DenmarkDüsseldorf, GermanyMünchen, GermanyHalle, Germany

Facts & assertions

4 sourced
Enrollment
536
Phase
PHASE4
Primary Completion Date
2020-08-26
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Paliperidone
drug
lead_sponsor
UMC Utrecht
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Rene S Kahn, professor
person
Wolfgang Fleischhacker, professor
person
Michael Davidson, professor
person